[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0821003B8 - método para aumentar a imunorreatividade - Google Patents

método para aumentar a imunorreatividade

Info

Publication number
BRPI0821003B8
BRPI0821003B8 BRPI0821003A BRPI0821003A BRPI0821003B8 BR PI0821003 B8 BRPI0821003 B8 BR PI0821003B8 BR PI0821003 A BRPI0821003 A BR PI0821003A BR PI0821003 A BRPI0821003 A BR PI0821003A BR PI0821003 B8 BRPI0821003 B8 BR PI0821003B8
Authority
BR
Brazil
Prior art keywords
immunoreactivity
increase
cells
antigen
increase immunoreactivity
Prior art date
Application number
BRPI0821003A
Other languages
English (en)
Inventor
Wolf Dominik
Baier Gottfried
Lametschwandtner Günther
Loibner Hans
Schuster Manfred
Original Assignee
Apeiron Biologics Ag
Medizinische Univ Innsbruck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biologics Ag, Medizinische Univ Innsbruck filed Critical Apeiron Biologics Ag
Publication of BRPI0821003A2 publication Critical patent/BRPI0821003A2/pt
Publication of BRPI0821003B1 publication Critical patent/BRPI0821003B1/pt
Publication of BRPI0821003B8 publication Critical patent/BRPI0821003B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

método para aumentar a imunorreatividade. a presente invenção refere-se a um método in vitro ou ex vivo para aumentar a imunorreatividade de células do sistema imunológico, que foram postas em contato com um antígeno, sendo que o referido método compreende a redução ou inibição da função de cb1-b das referidas células, aumentando a imunorreatividade das células em relação ao antígeno.
BRPI0821003A 2007-12-10 2008-12-10 método para aumentar a imunorreatividade BRPI0821003B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA1996/2007 2007-12-10
AT0199607A AT506041A1 (de) 2007-12-10 2007-12-10 Verfahren zur erhöhung der immunreaktivität
PCT/AT2008/000443 WO2009073905A2 (de) 2007-12-10 2008-12-10 Verfahren zur erhöhung der immunreaktivität

Publications (3)

Publication Number Publication Date
BRPI0821003A2 BRPI0821003A2 (pt) 2015-06-16
BRPI0821003B1 BRPI0821003B1 (pt) 2019-03-26
BRPI0821003B8 true BRPI0821003B8 (pt) 2021-05-25

Family

ID=40585504

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821003A BRPI0821003B8 (pt) 2007-12-10 2008-12-10 método para aumentar a imunorreatividade

Country Status (25)

Country Link
US (1) US8809288B2 (pt)
EP (2) EP3363892A1 (pt)
JP (2) JP6118491B2 (pt)
KR (1) KR101692797B1 (pt)
CN (2) CN101918544B (pt)
AT (1) AT506041A1 (pt)
AU (1) AU2008336276C1 (pt)
BR (1) BRPI0821003B8 (pt)
CA (1) CA2708343C (pt)
CY (1) CY1120136T1 (pt)
DK (1) DK2220214T3 (pt)
EA (1) EA018966B1 (pt)
ES (1) ES2665928T3 (pt)
HR (1) HRP20180558T1 (pt)
HU (1) HUE037235T2 (pt)
IL (1) IL206155A (pt)
LT (1) LT2220214T (pt)
MX (1) MX2010006296A (pt)
NZ (1) NZ585646A (pt)
PL (1) PL2220214T3 (pt)
PT (1) PT2220214T (pt)
RS (1) RS56941B1 (pt)
SI (1) SI2220214T1 (pt)
WO (1) WO2009073905A2 (pt)
ZA (1) ZA201003791B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2069381T3 (da) 2006-09-13 2016-03-14 Univ Columbia Midler og fremgangsmåder til udløsning af anti-tumorimmunrespons
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
EP2471548A1 (de) * 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
CN102552891A (zh) * 2011-12-27 2012-07-11 陆华 热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
ES2897579T3 (es) * 2013-06-10 2022-03-01 Dana Farber Cancer Inst Inc Métodos y composiciones para reducir la inmunosupresión por células tumorales
US10145908B2 (en) 2013-07-19 2018-12-04 Allegro Microsystems, Llc Method and apparatus for magnetic sensor producing a changing magnetic field
EP3254701A1 (en) 2016-06-09 2017-12-13 IMBA-Institut für Molekulare Biotechnologie GmbH Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections
CA3048979A1 (en) * 2016-12-30 2018-07-05 Celularity Inc. Genetically modified natural killer cells
US11766455B2 (en) * 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2020272937B2 (en) 2019-04-09 2024-09-26 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
AU2020278592B2 (en) 2019-05-17 2024-10-10 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
EP4003965A1 (en) 2019-07-30 2022-06-01 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
US20210085717A1 (en) 2019-09-24 2021-03-25 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for expansion of immune cells
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
EP4319739A2 (en) 2021-04-08 2024-02-14 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
CN115554290B (zh) * 2021-07-01 2025-02-14 中国科学院分子细胞科学卓越创新中心 五羟色胺或其受体激动剂在治疗ilc2细胞介导的免疫性疾病中的应用
EP4289939A1 (en) 2022-06-10 2023-12-13 Apeiron Biologics AG Population of transfected immune cells and method for their production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037989A1 (en) * 2001-08-27 2005-02-17 Lewis David L. Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
DE60335636D1 (de) * 2002-09-11 2011-02-17 Genentech Inc Zusammensetzungen und verfahren für die tumordiagnose und behandlung
EP1646644A4 (en) 2003-03-03 2007-05-16 Proteologics Inc POSH INTERACTIVE PROTEINS AND CORRESPONDING METHODS
US20070054355A1 (en) 2003-03-05 2007-03-08 Yuval Reiss Cbl-b polypeptides, complexes and related methods
ATE458485T1 (de) * 2003-07-11 2010-03-15 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
US20070274915A1 (en) * 2003-10-17 2007-11-29 Anjana Rao Modulation Of Anergy And Methods For isolating Anergy-Modulating Compounds
WO2005069791A2 (en) * 2004-01-08 2005-08-04 Cedars-Sinai Medical Center Compositions and methods for enhancing the th1 response in connection with dendritic cell vaccines
CN101437834B (zh) * 2004-07-19 2012-06-06 贝勒医学院 细胞因子信号转导调节剂的调节和用于免疫治疗的应用
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
TWI368637B (en) * 2005-09-05 2012-07-21 Hon Hai Prec Ind Co Ltd High lustrous nano paint and methods for manufacturing and using the same
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
DK2069381T3 (da) * 2006-09-13 2016-03-14 Univ Columbia Midler og fremgangsmåder til udløsning af anti-tumorimmunrespons
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität

Also Published As

Publication number Publication date
AU2008336276A1 (en) 2009-06-18
IL206155A0 (en) 2010-12-30
US20100260808A1 (en) 2010-10-14
HRP20180558T1 (hr) 2018-06-01
CA2708343A1 (en) 2009-06-18
JP2011507806A (ja) 2011-03-10
NZ585646A (en) 2012-05-25
EP2220214B1 (de) 2018-01-17
PL2220214T3 (pl) 2018-07-31
EP2220214A2 (de) 2010-08-25
EA018966B1 (ru) 2013-12-30
WO2009073905A2 (de) 2009-06-18
EP3363892A1 (de) 2018-08-22
EA201000974A1 (ru) 2010-12-30
SI2220214T1 (en) 2018-04-30
JP6175103B2 (ja) 2017-08-02
KR20100110779A (ko) 2010-10-13
AT506041A1 (de) 2009-05-15
BRPI0821003A2 (pt) 2015-06-16
CN103898051A (zh) 2014-07-02
AU2008336276B2 (en) 2014-06-12
HUE037235T2 (hu) 2018-08-28
KR101692797B1 (ko) 2017-01-05
WO2009073905A3 (de) 2009-10-22
ZA201003791B (en) 2011-03-30
US8809288B2 (en) 2014-08-19
IL206155A (en) 2014-07-31
JP2015231371A (ja) 2015-12-24
CN101918544A (zh) 2010-12-15
AU2008336276C1 (en) 2015-01-15
JP6118491B2 (ja) 2017-04-19
PT2220214T (pt) 2018-04-23
CN101918544B (zh) 2014-03-19
MX2010006296A (es) 2011-02-23
BRPI0821003B1 (pt) 2019-03-26
CA2708343C (en) 2018-09-04
DK2220214T3 (en) 2018-04-16
ES2665928T3 (es) 2018-04-30
RS56941B1 (sr) 2018-05-31
CN103898051B (zh) 2019-07-26
WO2009073905A8 (de) 2009-09-03
CY1120136T1 (el) 2018-12-12
LT2220214T (lt) 2018-03-26

Similar Documents

Publication Publication Date Title
BRPI0821003B8 (pt) método para aumentar a imunorreatividade
BR122018069446B8 (pt) método in vitro para detectar a presença de um célula de câncer em um indivíduo
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
BR112012012887A2 (pt) minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
BR112012010321B8 (pt) válvula de substituição para uso em um corpo humano
BR112012013975A2 (pt) anticorpos monoclonais que se ligam b7h6 e usos dos mesmo
BR112018000601A2 (pt) moléculas de anticorpo que se ligam ao cd22
ECSP12011796A (es) Anticuerpos monoclonales frente a progastrina y sus usos
WO2011056688A3 (en) Molecular profiling for personalized medicine
ES2530843T3 (es) Métodos basados en microARN para el diagnóstico de cáncer de páncreas
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BRPI0906549A8 (pt) bandagem médica
AR077334A1 (es) Anticuerpos muc1 antimucina
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
BRPI1014319A2 (pt) sistema para minimizar perda de circulação associada com a operação de um reservatório subterrâneo, e, método implementado por computador.
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
MX351889B (es) Composiciones y métodos anti-cxcr1.
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
GT200800172A (es) Vacuna de mycoplasma hyoneumoniae
WO2011035205A3 (en) Antibodies against candida, collections thereof and methods of use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF